Shanghai, China, March 23, 2023 - Rona Therapeutics, a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines, announced the appointments of Tony W. Ho, M.D., and Professor Aaron D. Gitler, to its scientific advisory board (SAB). The newly appointed SAB members will bring exceptional scientific expertise and global development strategy in building innovative RNA extrahepatic delivery pipeline.
"We are honored to have Tony W. Ho, M.D., and Professor Aaron D. Gitler, to join as SAB of Rona Therapeutics.” said Stella Shi, Founder and CEO of Rona Therapeutics, “Rona will work with renowned SAB members to expand frontiers of oligonucleotide therapeutics in its potential to address devastating diseases like neuro degenerative diseases. The depth of our SAB’s scientific expertise is of tremendous help in advancing pipeline of innovative oligonucleotide therapeutics beyond the liver.”
Tony W. Ho, M.D., served as Executive Vice President and Head of R&D for CRISPR Therapeutics between 2017 and 2021, responsible for global R&D across all therapeutic areas of the company. During this period, Dr. Ho led and built a world-leading R&D platform with more than 10 product pipelines. Dr. Ho and his team have brought the first CRISPR-based therapy CTX001, three allogeneic CAR-T (CTX110 (CD19), 120 (BCMA), 130 (CD70)), and the first CRISPR edited pancreatic islet progenitor cells (VCTX210) from research bench to the clinic. Prior to CRISPR Therapeutics, Dr. Ho was SVP and Head of Oncology Integration and Innovation at AstraZeneca and oversaw the development and commercialization of Lynparza® (olaparib) and Imfinizi® (durvalumab). Before joining AstraZeneca, Dr. Ho was the head of Neurology and Ophthalmology at Merck, and before Merck, Dr. Ho was the Co-Founder and CSO of Neuronyx.”
Dr. Ho received his M.D. from Johns Hopkins University and his B.S. in Electrical Engineering from UCLA. Dr. Ho has published more than 80 papers in a variety of fields and currently serves as an Adjunct Associate Professor of Neurology at the University of Pennsylvania and Assistant Professor of Neurology at Johns Hopkins University. ”
Dr. Ho said: “I am impressed by Rona’s breakthrough in oligonucleotide drug delivery and chemical modification, and its innovative pipeline. I am delighted to be Rona Therapeutics’ scientific advisor and help to advance its differentiated delivery system and pipeline to the clinic and benefit patients world-wide.”
Aaron D. Gitler, Ph.D., is a Professor in the Department of Genetics and he holds The Stanford Medicine Basic Science Professor endowed chair. His research uses a combination of yeast and human genetics to define mechanisms of neurodegenerative disease and has focused on Parkinson’s disease and ALS. One of his most pivotal discoveries was the identification of a major genetic contributor to ALS. His team recently demonstrated that inhibiting this gene markedly extends lifespan and improves motor performance in a mouse model of ALS, setting the stage for testing this therapeutic approach in human ALS. He has also uncovered the mechanism by which mutations in other genes cause ALS and has discovered a broad role for RNA-binding proteins in ALS and related human neurological diseases. Professor Gitler’s work has also helped to uncover an unexpected and novel therapeutic target for ALS.
Prior to Stanford, he was an assistant professor of cell and developmental biology at the University of Pennsylvania. Professor Gitler was a Pew Scholar in the Biomedical Sciences, a Rita Allen Foundation Scholar, and a recipient of the NIH Director's New Innovator. Award and the NIH NINDS Research Program Award.
Professor Gitler holds a bachelor’s degree from Pennsylvania State University and Ph.D. from the University of Pennsylvania.
Professor Gitler said: "Neurodegenerative diseases are in urgent need of better treatments. I admire Rona’s
determination, technology accumulation and forward-looking planning in this field. Through close cooperation between academia and industry, we believe the potential of nucleic acid drugs to solve the pathogenesis of neurodegenerative diseases, and there is great potential for more disease areas in the future."
Since Rona’s inception, the company has been building and expanding its SAB with world-leading experts in innovative platform building, target selection, pipeline strategy, translational and clinical strategy. Rona transformed its advisors’ expertise of respective fields into the foundation for scientific decision-making and advancing best in class and first in class pipeline.
In addition to the newly appointed scientific advisors, Rona SAB members include exceptional scientific leaders in RNA biology, oligonucleotide delivery, CMC and clinical development, including Professor Chuan He, Ph.D., a global leader in RNA modification and tenured professor of chemistry at the University of Chicago; Dr. Roberto Guerciolini, M.D., a translational scientist in RNA modulation and co-founder of Dicerna Pharmaceutical; Dr. Ling Su, Ph.D., a seasoned industry leader of drug development and regulatory, Dr. James Summers, Ph.D., prior Vice President of Neuroscience Research at AbbVie, and Dr. G. Susan Srivatsa, an eminent expert in the field of oligonucleotide drug analysis and quality control.
.svg)
Shanghai, China, March 23, 2023 - Rona Therapeutics, a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines, announced the appointments of Tony W. Ho, M.D., and Professor Aaron D. Gitler, to its scientific advisory board (SAB). The newly appointed SAB members will bring exceptional scientific expertise and global development strategy in building innovative RNA extrahepatic delivery pipeline. Shanghai, China, March 23, 2023 - Rona Therapeutics, a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines, announced the appointments of Tony W. Ho, M.D., and Professor Aaron D. Gitler, to its scientific advisory board (SAB). The newly appointed SAB members will bring exceptional scientific expertise and global development strategy in building innovative RNA extrahepatic delivery pipeline.
"We are honored to have Tony W. Ho, M.D., and Professor Aaron D. Gitler, to join as SAB of Rona Therapeutics.” said Stella Shi, Founder and CEO of Rona Therapeutics, “Rona will work with renowned SAB members to expand frontiers of oligonucleotide therapeutics in its potential to address devastating diseases like neuro degenerative diseases. The depth of our SAB’s scientific expertise is of tremendous help in advancing pipeline of innovative oligonucleotide therapeutics beyond the liver.”
Tony W. Ho, M.D., served as Executive Vice President and Head of R&D for CRISPR Therapeutics between 2017 and 2021, responsible for global R&D across all therapeutic areas of the company. During this period, Dr. Ho led and built a world-leading R&D platform with more than 10 product pipelines. Dr. Ho and his team have brought the first CRISPR-based therapy CTX001, three allogeneic CAR-T (CTX110 (CD19), 120 (BCMA), 130 (CD70)), and the first CRISPR edited pancreatic islet progenitor cells (VCTX210) from research bench to the clinic. Prior to CRISPR Therapeutics, Dr. Ho was SVP and Head of Oncology Integration and Innovation at AstraZeneca and oversaw the development and commercialization of Lynparza® (olaparib) and Imfinizi® (durvalumab). Before joining AstraZeneca, Dr. Ho was the head of Neurology and Ophthalmology at Merck, and before Merck, Dr. Ho was the Co-Founder and CSO of Neuronyx.
Dr. Ho received his M.D. from Johns Hopkins University and his B.S. in Electrical Engineering from UCLA. Dr. Ho has published more than 80 papers in a variety of fields and currently serves as an Adjunct Associate Professor of Neurology at the University of Pennsylvania and Assistant Professor of Neurology at Johns Hopkins University.
Dr. Ho said: “I am impressed by Rona’s breakthrough in oligonucleotide drug delivery and chemical modification, and its innovative pipeline. I am delighted to be Rona Therapeutics’ scientific advisor and help to advance its differentiated delivery system and pipeline to the clinic and benefit patients world-wide.”
Aaron D. Gitler, Ph.D., is a Professor in the Department of Genetics and he holds The Stanford Medicine Basic Science Professor endowed chair. His research uses a combination of yeast and human genetics to define mechanisms of neurodegenerative disease and has focused on Parkinson’s disease and ALS. One of his most pivotal discoveries was the identification of a major genetic contributor to ALS. His team recently demonstrated that inhibiting this gene markedly extends lifespan and improves motor performance in a mouse model of ALS, setting the stage for testing this therapeutic approach in human ALS. He has also uncovered the mechanism by which mutations in other genes cause ALS and has discovered a broad role for RNA-binding proteins in ALS and related human neurological diseases. Professor Gitler’s work has also helped to uncover an unexpected and novel therapeutic target for ALS
Prior to Stanford, he was an assistant professor of cell and developmental biology at the University of Pennsylvania. Professor Gitler was a Pew Scholar in the Biomedical Sciences, a Rita Allen Foundation Scholar, and a recipient of the NIH Director's New Innovator Award and the NIH NINDS Research Program Award.
Professor Gitler holds a bachelor’s degree from Pennsylvania State University and Ph.D. from the University of Pennsylvania.
Professor Gitler said: "Neurodegenerative diseases are in urgent need of better treatments. I admire Rona’s determination, technology accumulation and forward-looking planning in this field. Through close cooperation between academia and industry, we believe the potential of nucleic acid drugs to solve the pathogenesis of neurodegenerative diseases, and there is great potential for more disease areas in the future."
Since Rona’s inception, the company has been building and expanding its SAB with world-leading experts in innovative platform building, target selection, pipeline strategy, translational and clinical strategy. Rona transformed its advisors’ expertise of respective fields into the foundation for scientific decision-making and advancing best in class and first in class pipeline.
In addition to the newly appointed scientific advisors, Rona SAB members include exceptional scientific leaders in RNA biology, oligonucleotide delivery, CMC and clinical development, including Professor Chuan He, Ph.D., a global leader in RNA modification and tenured professor of chemistry at the University of Chicago; Dr. Roberto Guerciolini, M.., a translational scientist in RNA modulation and co-founder of Dicerna Pharmaceutical; Dr. Ling Su, Ph.D., a seasoned industry leader of drug development and regulatory, Dr. James Summers, Ph.D., prior Vice President of Neuroscience Research at AbbVie, and Dr. G. Susan Srivatsa, an eminent expert in the field of oligonucleotide drug analysis and quality control.
About Rona TherapeuticsRona Therapeutics is a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines to deliver to patients around the world.
Backed by blue-chip investors, Rona has developed proprietary RAZOR™ platform to discover differentiated siRNA therapeutics from next-generation chemical modification and novel biological insights. Together with partners, Rona is dedicated to advancing transformative RNA therapeutics into clinic in metabolic syndrome, glomerulonephritis, CNS and ocular diseases. For more information, please visit www.ronatherapeutics.com.
.svg)
Email
沪ICP备2021031795号
.png)
Address